MoonLake Immunotherapeutics (MLTX) to Release Earnings on Monday

MoonLake Immunotherapeutics (NASDAQ:MLTX) is expected to be posting its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect MoonLake Immunotherapeutics to post earnings of ($0.91) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 14, 2026 at 9:30 AM ET.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.92) earnings per share for the quarter, hitting the consensus estimate of ($0.92). During the same period last year, the company earned ($0.72) EPS. On average, analysts expect MoonLake Immunotherapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

MoonLake Immunotherapeutics Stock Performance

MLTX traded up $0.84 during midday trading on Monday, hitting $17.57. 101,705 shares of the company were exchanged, compared to its average volume of 1,723,363. The company’s 50 day simple moving average is $17.55 and its 200 day simple moving average is $15.03. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of -4.97 and a beta of 1.02. The company has a current ratio of 9.27, a quick ratio of 9.27 and a debt-to-equity ratio of 0.24. MoonLake Immunotherapeutics has a 1-year low of $5.95 and a 1-year high of $62.75.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Wolfe Research raised MoonLake Immunotherapeutics from an “underperform” rating to an “outperform” rating and increased their price target for the stock from $12.00 to $24.00 in a research report on Monday, March 23rd. The Goldman Sachs Group cut MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and raised their target price for the company from $8.00 to $10.00 in a research report on Wednesday, January 14th. Zacks Research upgraded MoonLake Immunotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Rothschild & Co Redburn upgraded MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and raised their target price for the company from $12.00 to $40.00 in a research report on Thursday, March 19th. Finally, Royal Bank Of Canada raised their target price on MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the company a “sector perform” rating in a research report on Monday, March 2nd. Nine analysts have rated the stock with a Buy rating, four have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $23.08.

Insider Transactions at MoonLake Immunotherapeutics

In related news, Director Bvf Partners L. P/Il sold 3,750,000 shares of the firm’s stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $16.79, for a total value of $62,962,500.00. Following the transaction, the director directly owned 1,039,238 shares of the company’s stock, valued at approximately $17,448,806.02. This trade represents a 78.30% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Da Silva Jorge Santos sold 51,873 shares of the firm’s stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $18.23, for a total transaction of $945,644.79. Following the completion of the transaction, the chief executive officer directly owned 2,924,893 shares in the company, valued at $53,320,799.39. This represents a 1.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,900,000 shares of company stock worth $65,714,663 over the last 90 days. Insiders own 12.02% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Hsbc Holdings PLC purchased a new position in MoonLake Immunotherapeutics in the 4th quarter valued at about $147,000. Virtu Financial LLC purchased a new position in MoonLake Immunotherapeutics in the 4th quarter valued at about $166,000. T. Rowe Price Investment Management Inc. purchased a new position in MoonLake Immunotherapeutics in the 4th quarter valued at about $47,000. Vident Advisory LLC purchased a new position in MoonLake Immunotherapeutics in the 4th quarter valued at about $204,000. Finally, Virtus Investment Advisers LLC lifted its stake in MoonLake Immunotherapeutics by 595.8% in the 4th quarter. Virtus Investment Advisers LLC now owns 17,987 shares of the company’s stock valued at $237,000 after buying an additional 15,402 shares in the last quarter. 93.85% of the stock is owned by hedge funds and other institutional investors.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.